65 related articles for article (PubMed ID: 15491322)
21. Tissue prognostic biomarkers in primary cutaneous melanoma.
Mandalà M; Massi D
Virchows Arch; 2014 Mar; 464(3):265-81. PubMed ID: 24487785
[TBL] [Abstract][Full Text] [Related]
22. Construction and analysis of multiparameter prognostic models for melanoma outcome.
Rothberg BE; Rimm DL
Methods Mol Biol; 2014; 1102():227-58. PubMed ID: 24258982
[TBL] [Abstract][Full Text] [Related]
23. A signal transduction pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with progression in human melanoma.
Qu X; Shen L; Zheng Y; Cui Y; Feng Z; Liu F; Liu J
J Invest Dermatol; 2014 Jan; 134(1):159-167. PubMed ID: 23792459
[TBL] [Abstract][Full Text] [Related]
24. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.
Xie CM; Wei W; Sun Y
J Genet Genomics; 2013 Mar; 40(3):97-106. PubMed ID: 23522382
[TBL] [Abstract][Full Text] [Related]
25. Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27(Kip1) accumulation.
Sistrunk C; Kim SH; Wang X; Lee SH; Kim Y; Macias E; Rodriguez-Puebla ML
Am J Pathol; 2013 May; 182(5):1854-64. PubMed ID: 23474082
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of Skp2 protein in oral nevi and melanoma.
Benevenuto-de-Andrade BA; León JE; Carlos R; Delgado-Azañero W; Mosqueda-Taylor A; Paes-de-Almeida O
Med Oral Patol Oral Cir Bucal; 2013 May; 18(3):e388-91. PubMed ID: 23385514
[TBL] [Abstract][Full Text] [Related]
27. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma.
de Andrade BA; León JE; Carlos R; Delgado-Azañero W; Mosqueda-Taylor A; de Almeida OP
Head Neck Pathol; 2012 Sep; 6(3):297-304. PubMed ID: 22311377
[TBL] [Abstract][Full Text] [Related]
29. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Wang G; Chan CH; Gao Y; Lin HK
Chin J Cancer; 2012 Apr; 31(4):169-77. PubMed ID: 22200179
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
PLoS One; 2011 Feb; 6(2):e17578. PubMed ID: 21386910
[TBL] [Abstract][Full Text] [Related]
31. Nuclear translocation of Skp2 facilitates its destruction in response to TGFβ signaling.
Hu D; Liu W; Wu G; Wan Y
Cell Cycle; 2011 Jan; 10(2):285-92. PubMed ID: 21212736
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of SKP2 alterations in metastatic melanoma.
Rose AE; Wang G; Hanniford D; Monni S; Tu T; Shapiro RL; Berman RS; Pavlick AC; Pagano M; Darvishian F; Mazumdar M; Hernando E; Osman I
Pigment Cell Melanoma Res; 2011 Feb; 24(1):197-206. PubMed ID: 20883453
[TBL] [Abstract][Full Text] [Related]
33. Current concepts of metastasis in melanoma.
Zbytek B; Carlson JA; Granese J; Ross J; Mihm MC; Slominski A
Expert Rev Dermatol; 2008 Oct; 3(5):569-585. PubMed ID: 19649148
[TBL] [Abstract][Full Text] [Related]
34. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.
Gould Rothberg BE; Bracken MB; Rimm DL
J Natl Cancer Inst; 2009 Apr; 101(7):452-74. PubMed ID: 19318635
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB.
Lin HK; Wang G; Chen Z; Teruya-Feldstein J; Liu Y; Chan CH; Yang WL; Erdjument-Bromage H; Nakayama KI; Nimer S; Tempst P; Pandolfi PP
Nat Cell Biol; 2009 Apr; 11(4):420-32. PubMed ID: 19270694
[TBL] [Abstract][Full Text] [Related]
36. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.
He S; Zhang D; Cheng F; Gong F; Guo Y
Mol Biol Rep; 2009 Nov; 36(8):2153-63. PubMed ID: 19117119
[TBL] [Abstract][Full Text] [Related]
37. Melanoma biomarkers: current status and vision for the future.
Larson AR; Konat E; Alani RM
Nat Clin Pract Oncol; 2009 Feb; 6(2):105-17. PubMed ID: 19107110
[TBL] [Abstract][Full Text] [Related]
38. Skp2 regulates G2/M progression in a p53-dependent manner.
Hu R; Aplin AE
Mol Biol Cell; 2008 Nov; 19(11):4602-10. PubMed ID: 18716061
[TBL] [Abstract][Full Text] [Related]
39. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer.
Frescas D; Pagano M
Nat Rev Cancer; 2008 Jun; 8(6):438-49. PubMed ID: 18500245
[TBL] [Abstract][Full Text] [Related]
40. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
Carreira S; Goodall J; Denat L; Rodriguez M; Nuciforo P; Hoek KS; Testori A; Larue L; Goding CR
Genes Dev; 2006 Dec; 20(24):3426-39. PubMed ID: 17182868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
